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New preclinical antimalarial drugs potently inhibit hepatitis C virus 1 
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Abstract 23 
Background: Persistent hepatitis C virus (HCV) infection causes chronic liver diseases 24 
and is a global health problem. Although new triple therapy (pegylated-interferon, 25 
ribavirin, and telaprevir/boceprevir) has recently been started and is expected to achieve a 26 
sustained virologic response of more than 70% in HCV genotype 1 patients, there are 27 
several problems to be resolved, including skin rash/ageusia and advanced anemia. Thus a 28 
new type of anti-HCV drug is still needed. 29 
Methodology/principal Findings: Recently developed HCV drug assay systems using 30 
HCV-RNA-replicating cells (e.g., HuH-7-derived OR6 and Li23-derived ORL8) were 31 
used to evaluate the anti-HCV activity of drug candidates. During the course of the 32 
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evaluation of anti-HCV candidates, we unexpectedly found that two preclinical 33 
antimalarial drugs (N-89 and its derivative N-251) showed potent anti-HCV activities at 34 
tens of nanomolar concentrations irrespective of the cell lines and HCV strains of 35 
genotype 1b. We confirmed that replication of authentic HCV RNA was inhibited by 36 
these drugs. Interestingly, however, this anti-HCV activity did not work for JFH-1 strain 37 
of genotype 2a. We demonstrated that HCV RNA-replicating cells were cured by 38 
treatment with only N-89. A comparative time course assay using N-89 and interferon- 39 
demonstrated that N-89-treated ORL8 cells had more rapid anti-HCV kinetics than did 40 
interferon--treated cells. This anti-HCV activity was largely canceled by vitamin E. In 41 
combination with interferon- and/or ribavirin, N-89 or N-251 exhibited a synergistic 42 
inhibitory effect. 43 
Conclusions/Significance: We found that the preclinical antimalarial drugs N-89 and 44 
N-251 exhibited very fast and potent anti-HCV activities using cell-based 45 
HCV-RNA-replication assay systems. N-89 and N-251 may be useful as a new type of 46 
anti-HCV reagents when used singly or in combination with interferon and/or ribavirin. 47 
 48 
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Introduction 49 
   Hepatitis C virus (HCV) infection causes chronic hepatitis, which can lead to liver 50 
cirrhosis and hepatocellular carcinoma. Approximately 170 million people are infected 51 
with HCV worldwide, making HCV infection a serious global health problem [1]. HCV is 52 
an enveloped virus with a positive single-stranded RNA genome, and belongs to the 53 
Flaviviridae family. The HCV genome encodes a large polyprotein precursor of 54 
approximately 3000 amino acids, which is cleaved into 10 proteins in the following order: 55 
Core, envelope 1 (E1), E2, p7, non-structural 2 (NS2), NS3, NS4A, NS4B, NS5A, and 56 
NS5B [2, 3]. 57 
   Until last year, the combination of pegylated-interferon (PEG-IFN) with ribavirin 58 
(RBV) was the standard therapy, resulting in a sustained virologic response (SVR) in 59 
about half of the patients receiving this treatment [4]. Two inhibitors of HCV NS3-4A 60 
protease, telaprevir and boceprevir, were recently approved as the first directly acting 61 
antiviral reagents for the treatment of HCV genotype 1, and have been used in 62 
combination with PEG-IFN and RBV [5]. The SVR rate in the treatment of HCV 63 
genotype 1 using the new triple therapy is expected to be more than 70% [6, 7]. However, 64 
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several severe side effects have appeared, such as skin rash by telaprevir, ageusia by 65 
boceprevir, and advanced anemia by telaprevir/boceprevir [6, 7]. Furthermore, the rapid 66 
emergence of resistant viruses by treatment with telaprevir or boceprevir is also a serious 67 
problem [8, 9], since it is expected that these resistant viruses will exhibit a resistant 68 
phenotype against other NS3-4A inhibitors developed in the future [10]. Therefore, a new 69 
type of anti-HCV reagent without severe side effects or emergence of resistant virus is 70 
still needed [10], although several anti-HCV candidates, such as NS5A and NS5B 71 
inhibitors, are currently in phase II-III development [11]. 72 
   To date, human hepatoma cell line HuH-7-derived cells are used as the only the 73 
preferred culture system for robust HCV replication, and most studies on anti-HCV 74 
reagents are currently carried out using an HuH-7-derived cell culture system [12]. We 75 
also developed an HuH-7-derived drug assay system (OR6), in which genome-length 76 
HCV-RNA (O strain of genotype 1b derived from an HCV-positive healthy carrier) 77 
encoding renilla luciferase (RL) efficiently replicates [13]. Recently, we found a new 78 
human hepatoma cell line, Li23, that enables efficient HCV-RNA replication and 79 
persistent HCV production, and we developed Li23-derived assay systems (ORL8 and 80 
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ORL11)
 
[14] that are comparable to the OR6 assay system [13]. Since we indicated that 81 
the gene expression profile of Li23 cells was distinct from that of HuH-7 cells [15], we 82 
expected that anti-HCV targets in Li23-derived cells might be distinct from those in 83 
HuH-7-derived cells. Indeed, we recently found that 10 M (a clinically achievable 84 
concentration) of RBV efficiently inhibited HCV-RNA replication in the ORL8/ORL11 85 
assays, but not in the OR6 assay [16]. This finding led us to clarify the anti-HCV 86 
mechanism of RBV [16, 17]. Furthermore, we demonstrated that plural assay systems 87 
including OR6 and ORL8 were required for the objective evaluation of anti-HCV 88 
reagents [18]. In that study, we observed that the antimalarial drug artemisinin possessed 89 
weak anti-HCV activity, as reported previously [19]. 90 
   From these results, we considered that antimalarial drugs might be good candidates 91 
for anti-HCV reagents, since the proliferation of both HCV and malaria generally occurs 92 
in hepatocytes. We therefore examined the anti-HCV activity of two preclinical 93 
antimalarial drugs, N-89 and its derivative water soluble N-251, which were previously 94 
discovered by our group as promising antimalarial reagents [20-22]. Here we report that 95 
N-89 and N-251 exhibit very fast and potent anti-HCV activities and have promise as 96 
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potential anti-HCV drugs. 97 
 98 
Materials and Methods 99 
Cell Culture 100 
   RSc and D7 cells were derived from the cell lines HuH-7 and Li23, respectively, were 101 
cultured as described previously [14, 23]. HuH-7-derived OR6 [13], AH1R [24], and 102 
1B-4R [Ikeda et al., submitted] cells harboring genome-length HCV-RNA and 103 
HuH-7-derived polyclonal sOR [25], and RSc-JRN/35B [Ikeda et al., submitted] cells 104 
harboring an HCV subgenomic replicon were cultured with medium in the presence of 105 
G418 (0.3 mg/ml) as described previously [13]. Li23-derived ORL8 [14], ORL11 [14], 106 
1B-4RL [Ikeda et al., submitted], and KAH5RL [Ikeda et al., submitted] cells harboring 107 
genome-length HCV-RNA were maintained with medium in the presence of G418 (0.3 108 
mg/ml) as described previously [14]. Li23-derived polyclonal sORL8 and sORL11 cells 109 
harboring an HCV replicon, which were established by the transfection of 110 
ORN/3-5B/QR,KE,SR RNA into the cured OL8 and OL11 cells, respectively, were also 111 
cultured with medium in the presence of G418 (0.3 mg/ml) as described previously [14]. 112 
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Cured cells, from which the HCV-RNA had been eliminated by IFN treatment, were also 113 
maintained with medium in the absence of G418 as described previously [13]. 114 
 115 
Reagents 116 
   N-89 and N-251 were synthesized according to the methods described previously 117 
[20-22]. RBV was kindly provided by Yamasa (Chiba, Japan). Human IFN- and vitamin 118 
E (VE) were purchased from Sigma–Aldrich (St. Louis, MO). Cyclosporine A (CsA) was 119 
purchased from Tokyo Chemical Industry (Tokyo, Japan). Artemisinin was purchased 120 
from Alexis Biochemicals (San Diego, CA). 121 
  122 
RL Assay 123 
   RL assay was performed as described previously [14, 18]. Briefly, the cells were 124 
plated onto 24-well plates (2 x 10
4
 cells per well) in triplicate and then treated with each 125 
reagent at several concentrations for 72 hrs. After treatment, the cells were subjected to 126 
luciferase assay using the RL assay system (Promega, Madison, WI). The experiments 127 
were performed at least in triplicate. From the assay results, the 50% effective 128 
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concentration (EC50) of each reagent was determined. 129 
 130 
WST-1 Cell Proliferation Assay 131 
   The WST-1 cell proliferation assay was performed as described previously [18]. 132 
Briefly, The cells were plated onto 96-well plates (1 x 10
3
 cells per well) in triplicate and 133 
then treated with each reagent at several concentrations for 72 hrs. After treatment, the 134 
cells were subjected to the WST-1 cell proliferation assay (Takara Bio, Otsu, Japan) 135 
according to the manufacturer’s protocol. The experiments were performed at least in 136 
triplicate. From the assay results, the 50% cytotoxic concentration (CC50) of each reagent 137 
was determined. 138 
 139 
Western Blot Analysis 140 
   The preparation of cell lysates, sodium dodecyl sulfate-polyacrylamide gel 141 
electrophoresis, and immunoblotting analysis were performed as previously described 142 
[26]. The antibodies used in this study were those against HCV Core (CP11; Institute of 143 
Immunology, Tokyo, Japan), NS5B (a generous gift from Dr. M. Kohara, Tokyo 144 
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Metropolitan Institute of Medical Science), and -actin (AC-15; Sigma–Aldrich) as the 145 
control for the amount of protein loaded per lane. 146 
 147 
Selective Index (SI) 148 
   The SI value of each reagent was determined by dividing the CC50 value by the EC50 149 
value. 150 
 151 
HCV Infection 152 
   HCV infection was performed as described previously [23]. RSc and D7 cells were 153 
inoculated with supernatant from RSc cells replicating JR/C5B/BX-2 [23]. 154 
 155 
Statistical Analysis 156 
   Determination of the significance of differences among groups was assessed using the 157 
Student’s t-test. P<0.05 was considered significant. 158 
 159 
Results 160 
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Preclinical antimalarial drugs, N-89 and N-251, showed potent 161 
anti-HCV activities in both HuH-7- and Li23-derived genome-length 162 
HCV-RNA-replicating cells 163 
   Recently we demonstrated that plural HCV assay systems developed using both 164 
HuH-7 and Li23 cell lines or HCV strains belonging to genotype 1b are required for the 165 
objective evaluation of anti-HCV candidates [18]. In the present work, we used our 166 
previously developed HCV assay systems to evaluate preclinical antimalarial drugs (N-89 167 
and N-251). N-89 (1,2,6,7-Tetraoxaspiro[7.11]nonadecane) is a chemically synthesized  168 
endoperoxide compound (Fig. 1A) with potent antimalarial activity against Plasmodium 169 
falciparum in vitro and Plasmodium berghei in vivo, and it shows low levels of 170 
cytotoxicity in mice and rats (50% lethal dose: >2000 mg/kg) [20, 27, 28]. N-251 171 
(6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol), which bears a functional side 172 
chain hydroxyl group that allows derivatization, is synthesized by replacing the hydrogen 173 
at C-4 of N-89 with hexanol (Fig. 1A), and it is as potent as N-89 against malaria 174 
parasites [21, 22]. We first evaluated the anti-HCV activities of N-89 and N-251 using 175 
HuH-7-derived OR6 and Li23-derived ORL8 and ORL11 assay systems. The results 176 
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revealed that both N-89 and N-251 possessed strong anti-HCV activities (Fig. 1B and C). 177 
The EC50 and SI values of N-89 in each assay were calculated (EC50 0.66 M, SI 14 in 178 
OR6 assay; EC50 0.089 M, SI 26 in ORL8 assay; EC50 0.045 M, SI 12 in ORL11 179 
assay) (Table 1), and the anti-HCV activity of N-251 was found to be as potent as that of 180 
N-89 (Table 1). The anti-HCV activities of N-89 and N-251 were confirmed by Western 181 
blot analysis of HCV Core (Fig. 1B and C). To further evaluate the activities of N-89 and 182 
N-251, as additional assay systems, we used HuH-7-derived 1B-4R (1B-4 strain [25] of 183 
genotype 1b derived from an HCV-positive healthy carrier) [Ikeda et al., submitted] and 184 
AH1R (an AH1 strain [29] of genotype 1b derived from a patient with acute hepatitis C) 185 
[24], and Li23-derived 1B-4RL (1B-4 strain [25]) and KAH5RL (KAH5 strain [25] of 186 
genotype 1b derived from a patient with acute hepatitis C) [Ikeda et al., submitted]. These 187 
assays also showed that N-89 and N-251 possessed potent anti-HCV activities (Fig. 188 
S1A-D and Table 1). It was noteworthy that N-89 exhibited the strongest anti-HCV 189 
activity (EC50 0.025 M; SI >20) in the AH1R assay (Fig. S1A and Table 1). These 190 
results suggest that the anti-HCV activity of N-89 or N-251 is not influenced by the cell 191 
line or HCV strain. We next examined the activities of N-89 and N-251 using polyclonal 192 
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cell-based assay systems (HuH-7-derived sOR [25], Li23-derived sORL8 and sORL11 193 
[16]) that facilitate the monitoring replication of HCV subgenomic replicon RNA. These 194 
assays also showed that N-89 and N-251 possessed anti-HCV activity with EC50 values of 195 
less than 1 M (Fig. S1E-G and Table 1). Taken together, these results indicate that the 196 
anti-HCV activities of N-89 and N-251 are not dependent on the specific cloned cell line 197 
or HCV structural proteins. 198 
 199 
N-89 and N-251 inhibited authentic HCV-RNA replication 200 
   The genome-length HCV-RNA used in the assay systems described above contains 201 
three non-natural elements: RL, neomycin phosphotransferase, and an internal ribosomal 202 
entry site of encephalomyocarditis virus. To exclude the possibility that the anti-HCV 203 
activity of N-89 or N-251 was due to the inhibition of these three exogenous elements, we 204 
examined the anti-HCV activities of N-89 and N-251 using the authentic 9.6 kb 205 
HCV-RNA-replicating HCV-O/RLGE cells [30], which were developed by the 206 
introduction of in vitro synthesized HCV-O/RLGE RNA (Fig. 2A) into OR6c cured cells. 207 
We could demonstrate by Western blot analysis that N-89 and N-251 at the expected 208 
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concentrations efficiently prevented HCV Core expression in HCV-O/RLGE cells in a 209 
dose-dependent manner (Fig. 2B). To further confirm that N-89 or N-251 does not inhibit 210 
the RL activity, we examined the direct effect of each reagent by adding it along with 211 
substrate to the cell lysate in the RL assay. No suppressive effects by N-89 and N-251 212 
were observed in either the OR6 assay (Fig. S2A) or the ORL8 assay (Fig. S2B). These 213 
results indicate that the anti-HCV activities of N-89 and N-251 were due to the inhibition 214 
of HCV-RNA itself, but not to exogenous elements contained in the genome-length 215 
HCV-RNA. 216 
 217 
N-89 and N-251 did not inhibit RNA replication of HCV JFH-1 strain 218 
   We next examined whether N-89 and N-251 worked in an HCV production system 219 
using HCV-JFH-1 strain (genotype 2a). Unexpectedly, the results using the JFH-1 220 
reporter assay systems [23], which were recently developed using HuH-7-derived RSc 221 
and Li23-derived D7 cells, revealed that both N-89 and N-251 did not show anti-HCV 222 
activity for the HCV-JFH-1 strain (Fig. 2C, Fig. S3). To clarify whether anti-HCV 223 
activity depends on the difference of genotype or assay model, we evaluated the activities 224 
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of N-89 and N-251 using RSc-JRN/35B [Ikeda et al., submitted] cells harboring a 225 
subgenomic HCV-JFH-1 replicon as an additional assay. The results revealed that N-89 226 
and N-251 did not show any anti-HCV activities in this assay system either (Fig. 2D). 227 
These results suggest that the inhibitory effect of N-89 or N-251 on HCV RNA 228 
replication may depend on genotype 1b or not work for only JFH-1 strain. 229 
 230 
OR6 and ORL8 cells were cured by treatment with only N-89 231 
   To date, IFN- alone or IFN- alone has generally been used to prepare cured cells 232 
from the cells harboring HCV-RNA [31]. Since we observed strong anti-HCV activity 233 
(>99% suppression) at 8 M of N-89 in OR6 cells or 1 M of N-89 in ORL8 cells 234 
without a decrease in cell viability (Fig. 1B), we expected that these cells might be cured 235 
only by treatment with N-89. Accordingly, OR6 and ORL8 cells were treated with 8 M 236 
and 1 M of N-89, respectively, in the absence of G418. The treatment was continued for 237 
3 weeks with the addition of N-89 at 4-day intervals. All of the treated cells were dead 238 
when cultured in the presence of G418 for an additional two weeks, whereas the treated 239 
cells proliferated efficiently in the absence of G418 (Fig. 3), suggesting that OR6 and 240 
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ORL8 cells are cured by monotherapy with N-89. This suggestion was confirmed by 241 
Western blot analysis (Fig. 3). These results indicate that N-89 is a strong anti-HCV 242 
reagent, which can be used to prepare cured cells by treatment at low concentration. 243 
 244 
Comparative time course assay of the anti-HCV activities of N-89 and 245 
IFN- 246 
   We next performed a time course assay (2 to 72 hrs after treatment) in the case of 247 
ORL8 cells treated with N-89 (0.1 M or 1 M) or IFN- (1 IU/ml; corresponding to 248 
approximately EC80). ORL8 cells treated with IFN- (1 IU/ml) and N-89 (1 M) had 249 
almost the same anti-HCV kinetics over the first 24 hrs after treatment (upper panel of Fig. 250 
4); however, within the first 12 hrs after treatment N-89-treated ORL8 cells had more 251 
rapid anti-HCV kinetics than did the IFN--treated cells (lower panel of Fig. 4). N-89 at 252 
concentrations of 0.1 M and 1 M led to significantly decreased RL activity at 9 hrs and 253 
6 hrs, respectively, after treatment, whereas a decrease of RL activity in the cells treated 254 
with 1 IU/ml of IFN- began to be seen at 12 hrs after treatment (lower panel of Fig. 4). 255 
These results suggest that the action of N-89, and probably also that of N-251, is faster 256 
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than that of IFN-, and the anti-HCV mechanism of N-89 is different from that of IFN-. 257 
 258 
The anti-HCV activities of N-89 and N-251 were completely canceled by 259 
VE 260 
   We previously reported that the antioxidant VE canceled the anti-HCV activities of 261 
CsA and three nutrients (-carotene, vitamin D2, and linoleic acid) [32], and demonstrated 262 
that the oxidative stress induced by these anti-HCV reagents caused anti-HCV status via 263 
activation of the extracellular signal-regulated kinase signaling pathway [33]. To evaluate 264 
this possibility, we examined the effect of VE on N-89 at the EC90 level in the ORL8 265 
assay. CsA and IFN- were also used as a positive and a negative control, respectively, 266 
on the effect of VE in the ORL8 assay. The results revealed that the anti-HCV activities 267 
of N-89 and CsA were largely canceled by VE, whereas the activity of IFN- was not 268 
canceled (Fig. 5A). We normalized these results by dividing the RL value obtained in the 269 
presence of VE by that in the absence of VE as described previously [16, 32]. The values 270 
of N-89 and CsA were 16 and 34, respectively, whereas the value (3.2) of IFN- was 271 
almost the same as that (3.0) of the control (Fig. 5B). Similar results were obtained by 272 
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using N-251 (Fig. 5C and D). The values of N-251, CsA, and IFN- were 13, 19, and 4.3, 273 
respectively, in comparison with the value (2.3) of the control (Fig. 5D). These results 274 
suggest that the induction of oxidative stress is associated with the anti-HCV activity of 275 
N-89 or N-251. However, an antimalarial drug, artemisinin, was hardly influenced by 276 
co-treatment with VE (Fig. 5E). The value (1.9) of artemisinin was almost the same as 277 
that (3.5 or 2.5) of IFN- or the control, respectively (Fig. 5F). These results were also 278 
confirmed by Western blot analysis of HCV Core (Fig. 5G). Therefore, our results 279 
suggest that the anti-HCV mechanism of artemisinin is not associated with the induction 280 
of oxidative stress, and is distinct from that of N-89 or N-251.   281 
 282 
Synergistic effect of anti-HCV activity by N-89 or N-251 in combination 283 
with IFN- and/or RBV 284 
  We examined the anti-HCV activity of N-89 or N-251 in combination with IFN- 285 
using OR6 and ORL8 assay systems. The results of the ORL8 assay revealed that the 286 
anti-HCV activity of N-89 or N-251 in combination with IFN- (more than 4 IU/ml) was 287 
significantly stronger than that expected as an additive effect, suggesting a synergistic 288 
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effect of N-89 or N-251 and IFN- (Fig. 6A). However, such an effect was not clear in 289 
the OR6 assay (Fig. S4A). We next examined the combination effect of RBV in the same 290 
way as IFN- using an ORL8 assay. We observed that the anti-HCV activity of N-89 or 291 
N-251 in combination with RBV was significantly stronger than that expected additively, 292 
suggesting that there was a synergistic effect between N-89 or N-251 and RBV (Fig. 6B). 293 
However, in the OR6 assay, we noticed that RBV showed an additive anti-HCV effect in 294 
combination with N-89 or N-251 (Fig. S4B). Since RBV has been shown to have little 295 
anti-HCV activity in the OR6 assay system [16], some specific factor(s) in ORL8 cells 296 
might contribute to the synergistic effect of N-89 or N-251 in combination with RBV. 297 
Therefore, we further examined the effect of N89 or N-251 in combination with both 298 
IFN- and RBV using an ORL8 assay. As expected, the anti-HCV activity of N-89 or 299 
N-251 was synergistically enhanced in combination with both IFN- and RBV in the 300 
ORL8 assay (Fig. 6C). On the other hand, in the OR6 assay, a synergistic effect like that 301 
seen in the ORL8 assay was not observed (Fig. S4C). We confirmed that any such 302 
synergistic effect was not due to the cell toxic effect (Fig. S5). 303 
 304 
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Discussion 305 
   N-89 and its derivative N-251 are preclinical and promising drugs possessing 306 
antimalarial activities in vitro and in vivo comparable to those of artemisinin [20, 21]. In 307 
the present study, using cell-based HCV-RNA-replication assay systems, we found that 308 
N-89 and N-251 possessed potent anti-HCV activities irrespective of the cell lines and 309 
HCV strains of genotype 1b, and that they did not work for JFH-1 strain of genotype 2a. 310 
Furthermore, We demonstrated that the anti-HCV kinetics of N-89 was faster than that of 311 
IFN-, and that both N-89 and N-251 exhibited synergistic effects in combination with 312 
IFN- and/or RBV. 313 
   Along with the worldwide spread of HCV, high prevalence areas of HCV infection 314 
have overlapped with endemic areas of malaria infection [34, 35]. It is also interesting 315 
that the liver is a target organ for the replication of HCV and malaria. This fact would 316 
again suggest that N-89 and N-251 target a coon factor that is required for the replication 317 
of HCV and malaria. At the same time, N-89 and N-251 have become readily and cheaply 318 
available due to their ease of synthesis [20, 21]. Since we showed that 319 
HCV-RNA-replicating cells were cured by monotherapy with N-89, monotherapy with 320 
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N-89 or N-251 would be simultaneously effective for the diseases caused by malaria and 321 
HCV infection. Furthermore, we recently showed that the blood concentration of N-89 or 322 
N-251 reaches approximately 1 M [Kim et al., unpublished data]. Since this 323 
concentration, which is equivalent to the EC99 value of N-89 in the ORL8 assay, was used 324 
for the preparation of cured cells, even monotherapy with N-89 would be useful for 325 
patients with chronic hepatitis C.  326 
   In regard to the anti-HCV mechanism of N-89 and N-251, we provided evidence that 327 
the anti-HCV activity of these reagents was canceled by antioxidant VE, suggesting the 328 
induction of oxidative stress. To identify the target factor(s) located downstream of ROS 329 
production, we attempted microarray analysis using OR6 and ORL8 cells treated with 330 
N-89. However, consequently, we failed to obtain the candidate gene indicating the 331 
meaningful expression level, although we identified several genes, which were commonly 332 
upregulated or downregulated in the N-89-treated cells (Fig. S6). To clarify the factor(s), 333 
further analysis will be needed.  334 
   The synergistic anti-HCV effect of N-89 or N-251 in combination with RBV rather 335 
than IFN- is also interesting. Using RBV-sensitive ORL8 cells, we recently clarified that 336 
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the anti-HCV mechanism of RBV was mediated by the inhibition of IMPDH, which is 337 
required for HCV-RNA replication [16]. In addition, since RBV is an important 338 
component of current IFN-based therapies, including the recently developed triple therapy, 339 
the use of N-89 or N-251 may further enhance the SVR rate achieved with the current 340 
therapy. To evaluate this possibility, we compared the SI values of N-89, N-251, RBV, 341 
and CsA using the ORL8 assay system. The results revealed that the SI values of N-89, 342 
N-251, RBV, and CsA were 26, 13, 10, and 15, respectively, indicating that the anti-HCV 343 
activity of N-89 or N-251 is equivalent to that of RBV or CsA. Since the treatment with 344 
N-89/N-251 and RBV exhibits a synergistic effect, oral N-89 or N-251 would be good 345 
compounds for inclusion in the current triple therapy. 346 
   In conclusion, we found that two oral antimalarial drugs in the preclinical stage of 347 
development (N-89 and N-251) exhibited strong anti-HCV activities to genotype 1b. 348 
These compounds would have potential as one component of a therapeutic regimen based 349 
on combinations of HCV-specific inhibitors. 350 
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 465 
Figure Legends 466 
Figure 1. Anti-HCV activities of N-89 and N-251 detected in the OR6, ORL8, and 467 
ORL11 assays. (A) Structures of N-89 and N-251. (B) Effects of N-89 on genome-length 468 
HCV-RNA replication. OR6, ORL8, and ORL11 cells were treated with N-89 for 72 hrs, 469 
followed by RL assay and WST-1 assay. The relative value (%) calculated at each time 470 
point, when the level in non-treated cells was assigned as 100%, is presented here. Data 471 
are expressed as the means±standard deviation of triplicate assays. Western blot analysis 472 
of the treated cells for the HCV Core was also performed. (C) Effects of N-251 on 473 
genome-length HCV-RNA replication. The RL assay, WST-1 assay, and Western blot 474 
analysis were performed as described in (B).  475 
 476 
Figure 2. Characterization of anti-HCV activities of N-89 and N-251. (A) Schematic 477 
gene organization of authentic HCV-RNA. The positions of four adaptive mutations are 478 
indicated by a black star. (B) N-89 and N-251 inhibited authentic HCV-RNA replication. 479 
The cells harboring HCV-O/RLGE RNA
 
[30] were treated with N-89 and N-251 for 72 480 
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hrs, and then Western blot analysis was performed as described in Fig. 1B. (C) N-89 did 481 
not inhibit the HCV-JFH-1 replication. RSc and D7 cells were inoculated with 482 
supernatant from RSc cells replicating JR/C5B/BX-2 [23]. The RL assay was performed 483 
as described in Fig. 1B. (D) N-89 and N-251 did not inhibit the replication of HCV-JFH-1 484 
subgenomic replicon. The RL and WST-1 assays were performed as described in Fig. 1B. 485 
 486 
Figure 3. OR6 and ORL8 cells were cured by treatment with only N-89. The treated 487 
cells were divided into two plates with or without G418, and then cultured for 2 weeks. 488 
Coomassie brilliant blue staining (left panels) and Western blot analysis (right panels) 489 
were performed.  490 
 491 
Figure 4. The anti-HCV action of N-89 was faster than that of IFN-The ORL8 cells 492 
were treated with N-89 or IFN-, and then RL assays were performed at 2 to 72 hrs after 493 
the treatment. The relative value (%) calculated at each time point, when the luciferase 494 
activity of non-treated cells at 24 hrs was assigned as 100%, is shown. Data are expressed 495 
as the means±standard deviation of triplicate assays.  496 
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 497 
Figure 5. The anti-HCV activity of N-89 or N-251 was canceled by addition of VE. 498 
Effect of VE on the anti-HCV activity of N-89 (A), N-251 (C), Artemisinin (E), CsA, or 499 
IFN- at the expected EC90. ORL8 cells were treated with control medium (-), N-89, CsA, 500 
or IFN- in either the absence or presence of VE for 72 hrs. After treatment, an RL assay 501 
of harvested ORL8 cell samples was performed. (B, D, and F) The ratio of RL activity in 502 
the presence of VE to the RL activity in the absence of VE. The above ratio was 503 
calculated from the data of (A, C, and E). The horizontal line indicates the promoting 504 
effect of VE alone on HCV-RNA replication as a baseline. (G) Western blot analysis was 505 
performed as described in Fig. 1B. 506 
 507 
Figure 6. Synergistic anti-HCV effects of N-89 or N-251 in combination with IFN- 508 
and/or RBV on HCV RNA replication in ORL8 cells. Open symbols in the broken 509 
lines show the values expected as an additive anti-HCV effect and closed symbols in the 510 
solid lines show the values obtained by the ORL8 assay. ORL8 cells were treated with 511 
N-89 or N-251 in combination with IFN- (A), RBV (B), or IFN- and RBV (C) for 72 512 
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hrs and subjected to RL assay. 513 
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